References
- Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: Role of physicochemical properties of particulate carriers – liposomes and microspheres – on the phagocytosis by macrophages. J Control Release 2002; 79: 29–40
- Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982; 51: 531–54
- Croft SL, Davidson RN, Thornton EA. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrob Chemother 1991; 28(Suppl B)111–18
- Dube A, Gupta R, Singh N. Reporter genes facilitating discovery of drugs targeting protozoan parasites. Trends Parasitol 2009; 25: 432–9
- Fallon RJ, Schwartz AL. Receptor-mediated delivery of drugs to hepatocytes. Adv Drug Delivery Rev 1989; 4: 49–63
- Fernandez-Guerroro ML, Aguado JM, Buzcn L, Barros C, Montalban C, Martin T, Bouza E. Visceral leishmaniasis in immunocompromised hosts. Am J Med 1987; 83: 1098–102
- Gupta S, Dube A, Vyas SP. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. J Drug Target 2007a; 15: 437–44
- Gupta SK, Sisodia BS, Sinha S, Hajela K, Naik S, Shasany AK, Dube A. Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes. Proteomics 2007b; 7: 816–823
- Herwaldt BL. Leishmaniasis. The Lancet 1999; 354: 1191–9
- Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Controlled Release 2001; 73: 255–67
- Kumar P, Kumar A, Verma SS, Dwivedi N, Singh N, Siddiqi MI, Tripathi RP, Dube A, Singh N. Leishmania donovani pteridine reductase 1: Biochemical properties and structure-modeling studies. Exp Parasitol 2008; 120: 73–9
- Kumari S, Kumar A, Samant M, Singh N, Dube A. Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics. Curr Drug Targets 2008; 9: 938–47
- Kweon HY, Um IC, Park YH. Structural and thermal characteristics of Antheraea pernyi silk fibroin/chitosan blend film. Polymer 2001; 42: 6651–6
- Leo E, Cameroni R, Forni F. Dynamic dialysis for the drug release evaluation from doxorubicin-gelatin nanoparticle conjugates. Int J Pharm 1999; 180: 23–30
- Manandhar KD, Yadav TP, Prajapati VK, Kumar S, Rai M, Dube A, Srivastava ON, Sundar S. Antileishmanial activity of nano-amphotericin B deoxycholate. J Antimicrob Chemother 2008; 62: 376–80
- Melby PC, Chandrasekar B, Zhao W, Coe JE. The hamsters as a model of human visceral leishmaniasis: Progressive disease and impaired generation of nitric oxide in the face of a prominent Th-1 like cytokine response. J Immunol 2001; 166: 1912–20
- Misra P, Khaliq T, Dixit A, Sengupta S, Samant M, Kumari S, Kumar A, Kushawaha PK, Majumder HK, Saxena AK, et al. Antileishmanial activity mediated by apoptosis and structure-based target study of peganine hydrochloride dihydrate: An approach for rational drug design. J Antimicrob Chemother 2008; 62: 998–1002
- Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev 2001; 53: 283–318
- Mukherjee S, Das L, Kole L, Karmakar S, Datta N, Das PK. Targeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis. J Infect Dis 2004; 189: 1024–34
- Sett R, Basu N, Ghosh AK, Das PK. Potential of doxorubicin as an antileishmanial agent. J Parasitol 1992; 78: 350–4
- Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, Dhawan S. Chitosan microspheres as a potential carrier for drugs. Int J Pharm 2004; 274: 1–33
- Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347: 1739–46
- Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6: 849–54
- Tiyaboonchai W, Limpeanchob N. Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. Int J Pharm 2007; 329: 142–9
- Torchilin VP. Drug targeting. Eur J Pharm Sci 2000; 11(Suppl 2)S81–91
- Tripathi KD. Essentials of medical pharmacology. New Delhi,. Jaypee Brothers, Medical Publishers Pvt. Ltd, India 2000
- Wang YM, Sato H, Adachi I, Horikoshi I. Optimization of the formulation design of chitosan microspheres containing cisplatin. J Pharm Sci 1996; 85: 1204–10
- Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 2007; 25(11)2085–94